Which medications in the drug class Disease modifying agents are used in the treatment of Peripheral Ulcerative Keratitis?

Updated: Jun 11, 2019
  • Author: Ellen N Yu-Keh, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print

Disease modifying agents

These agents alter the immune response to diverse stimuli.

Infliximab (Remicade)

Chimeric IgG1k monoclonal antibody that neutralizes cytokine TNF-α and inhibits its binding to TNF-α receptor. Reduces infiltration of inflammatory cells and TNF-α production in inflamed areas. Used with methotrexate in patients who have had inadequate response to methotrexate monotherapy.

Rituximab (Rituxan)

It is a chimeric monoclonal antibody directed against the CD20 protein, which is found primarily on the surface of B cells.

Adalimumab (Humira)

A human monoclonal antibody against tumour necrosis factor (TNF).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!